ReviewInternational journal of molecular sciences2020
Airway Microbiota as a Modulator of Lung Cancer.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 65 citations in OpenAlex.
- The Effects of Smoking on Respiratory Microbiota Diversity and Composition: A Systematic Review with Exploratory Meta-Analysis.Microorganisms · 2026Review
- Fluoroquinolone Exposure and Cancer Risk in Interstitial Lung Disease: A Propensity-Score-Matched Cohort Study Using Cox and Competing-Risk Models.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Association between the oral microbiome and clinical indicators of resectable non-small cell lung cancer (NSCLC).Journal of oral microbiology · 2026Article
- Review
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Assessing Diversity Scaling in Lung Cancer Microbiome Across Individuals and Tissue Types.MicrobiologyOpen · 2025Article
- The Lung Microbiome and Its Impact on Obstructive Sleep Apnea: A Diagnostic Frontier.Diagnostics (Basel, Switzerland) · 2025Review
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025Review
- A Perspective on Lung Cancer and Lung Microbiome: Insight on Immunity.Immunity, inflammation and disease · 2025Review
- Respiratory microbiome-host interaction on lung carcinogenesis, immunity, and immunotherapy.Frontiers in immunology · 2025Review
- Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients.Translational lung cancer research · 2024Article
- The bacterial microbiome and cancer: development, diagnosis, treatment, and future directions.Clinical and experimental medicine · 2024Review
- Bronchoalveolar Lavage Fluid Microbiota is Associated with the Diagnosis and Prognosis Evaluation of Lung Cancer.Phenomics (Cham, Switzerland) · 2024Article
- Prediction of lung cancer using novel biomarkers based on microbiome profiling of bronchoalveolar lavage fluid.Scientific reports · 2024Article
- Diagnostic and prognostic values of NSCLC patients with or without obstructive pneumonia after sleeve lobectomy.Frontiers in cellular and infection microbiology · 2024Article
- Symbiotic microbial communities in various locations of the lung cancer respiratory tract along with potential host immunological processes affected.Frontiers in cellular and infection microbiology · 2024Review
- Review
- A Pilot Cross-Sectional Study of Immunological and Microbiome Profiling Reveals Distinct Inflammatory Profiles for Smokers, Electronic Cigarette Users, and Never-Smokers.Microorganisms · 2023Article
- The Impact of Smoking on Microbiota: A Narrative Review.Biomedicines · 2023Review
- Human microbiomes in cancer development and therapy.MedComm · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research on cancer-associated microbial communities has elucidated the interplay between bacteria, immune cells, and tumor cells; the bacterial pathways involved in the induction of carcinogenesis; and their clinical significance. Although accumulating evidence shows that a dysbiotic condition is associated with lung carcinogenesis, the underlying mechanisms remain unclear. Microorganisms possibly trigger tumor initiation and progression, presumably via the production of bacterial toxins and other pro-inflammatory factors. The purpose of this review is to discuss the basic role of the airway microbiome in carcinogenesis and the underlying molecular mechanisms, with the aim of developing anticancer strategies involving the airway microbiota. In addition, the mechanisms via which the microbiome acts as a modulator of immunotherapies in lung cancer are summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.